TIANFU CHEM AZD-9291 CAS NO.1421373-65-0

product name: azd-9291
synonyms: azd9291, >=98%;azd9291 (free base);osimertinib (azd-9291);zad9291;azd9291, osimertinib;azd9291 base;osimertinib base;n-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1h-indol-3-yl)pyrimidin
cas: 1421373-65-0
mf: c28h33n7o2
mw: 499.61
einecs:
product categories: inhibitors;anticancer;azd9291;api
mol file: 1421373-65-0.mol
azd-9291 structure

azd-9291 usage and synthesis
uses azd-9291 (osimertinib) is a oral, third generation, small-molecule epidermal growth factor receptor (egfr) inhibitor and antineoplastic agent. in addition, it is a cytochrome p450 3a inhibitor, and cytochrome p450 3a4 inducer, and cytochrome p450 1a2 inducer, and breast cancer resistance protein inhibitor. it is used for the treatment of advanced non-small cell lung cancer (nsclc) where mutant egfr form (such as t790m) is often presented. through suppressing the egfr-mediated signalling, it cause cell death and inhibit tumour growth in related cancer cells.
description azd-9291 (mesylate), also known as osimertinib, belongs to a third-generation egfr (epidermal growth factor receptor) inhibitor. it can be used for the treatment of locally advanced or metastatic non-small cell lung cancer (nsclc) in case when the cancer cells carry specific mutations (such as t790m) in the epidermal growth factor receptor. it takes effect through directly binding to the certain mutant forms of egfr (t790m, l858r, and exon 19 deletions) that are frequently found in nsclc, further causing poor prognosis for late-stage disease. since it spares wild type egfr during therapy, it has only limited toxicity.
definition chebi: a member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. used (as the mesylate salt) for treat ent of egfr t790m mutation positive non-small cell lung cancer.